<DOC>
	<DOCNO>NCT01602380</DOCNO>
	<brief_summary>The purpose study compare treatment Fulvestrant ( FASLODEX ) Anastrozole ( ARIMIDEX ) effect disease progression woman locally advance metastatic breast cancer prior hormonal treatment .</brief_summary>
	<brief_title>A Global Study Compare Effects Fulvestrant Arimidex Subset Patients With Breast Cancer .</brief_title>
	<detailed_description>A Randomised , Double-blind , Parallel-group , Multicentre , Phase III Study Compare Efficacy Tolerability Fulvestrant ( FASLODEX ) 500 mg Anastrozole ( ARIMIDEX ) 1 mg Hormonal Treatment Postmenopausal Women Hormone Receptor-Positive Locally Advanced Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Histological confirmation breast cancer post menopausal woman ( age &gt; =60 ) . Positive hormone receptor status ( ER +ve and/or PgR +ve ) primary metastatic tumour tissue base local laboratory assessment . EITHER locally advance disease ( 1 line chemotherapy allow remain unsuitable therapy curative intent ) OR Metastatic disease . ( 1 line chemotherapy breast cancer allow subsequent evidence progressive disease ) At least 1 lesion ( measurable and/or nonmeasurable ) accurately assessed baseline suitable repeat assessment . Postmenopausal woman , fulfil 1 : Prior bilateral oophorectomy Age &gt; 60 year Age &lt; 60 year amenorrheic 12+months absence chemotherapy , tamoxifen , toremifene , ovarian suppression FSH oestradiol postmenopausal range Presence lifethreatening metastatic disease Any : Extensive hepatic involvement involve brain meninges symptomatic pulmonary lymph spread Discrete lung metastasis acceptable respiratory function significantly compromise Prior systemic therapy breast cancer one line cytotoxic chemotherapy ( last dose chemotherapy must receive 28 day prior randomisation ) Radiation therapy complete within 28 day prior randomisation ( exception radiotherapy give control bone pain , start prior randomisation ) . Prior hormonal treatment breast cancer . Current prior malignancy within previous 3 year ( breast cancer adequately treat basal cell squamous cell carcinoma skin situ carcinoma cervix ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hormone receptor positive breast cancer</keyword>
	<keyword>endocrine</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>hormone</keyword>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>metastatic</keyword>
	<keyword>tumour</keyword>
</DOC>